pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
786
stories
1h
STAT+: How a simple UTI turns into a $1,756 bill
stat
14h
For Lilly, cash-pay is key in the US and, increasingly, abroad
endpoints
18h
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
biospace
20h
STAT+: El-Sayed claps back at RFK Jr., and FDA’s ‘enforcement discretion’ on peptides
stat
20h
LENZ cuts 75% of staff as third quarter earnings disappoint
biospace
20h
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
stat
21h
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
21h
STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more
stat
22h
Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
fiercebiotech
22h
Lilly again far surpasses revenue expectations
endpoints
1d
Opinion: Health care needs buyers willing to say no
stat
1d
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
stat
1d
Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial
fiercebiotech
1d
Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetes
raps
1d
STAT+: Lawmaker wants government watchdog to probe TrumpRx over claims about drug savings
stat
1d
STAT+: HHS moves to allow compounding of some unapproved peptides
stat
1d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
1d
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
stat
1d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
1d
Lilly shuffles business structure; Novartis writes off part of Avidity deal
biopharma dive
1d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
1d
What has actually caused the decline in drug overdose deaths?
stat
1d
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes
endpoints
1d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
2d
Have you been impacted by Epic’s actions?
stat
2d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
2d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
2d
5 new drug launches that defied industry expectations
biospace
2d
STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts
stat
2d
Lilly's ads can continue after Novo challenge, judge rules
endpoints
← prev
page 1 of 27
next →
